Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada-based Nymox Pharmaceutical has reported new positive data from a recently completed multi-center US clinical study of NX-1207, the company's new investigational drug for benign prostatic hyperplasia.
Subscribe to our email newsletter
The new evidence indicates that NX-1207 can markedly reduce the incidence of nocturia, a particularly bothersome symptom of nighttime urination associated with benign prostatic hyperplasia (BPH).
After 90 days, subjects treated with a therapeutic dose of NX-1207 had a mean 49% reduction in nocturia symptoms, which was statistically significant compared to baseline (p less than 0.001), the company said.
According to the company, NX-1207 has been shown to improve the signs and symptoms of BPH, producing an improvement which has been statistically significantly better than double-blinded placebo and study controls and is higher than the improvement reported for approved drugs for BPH.